Detail akcie Sopharma AD Sofia, Ordinary, MiFID Eligible Security, Warsaw Stock Exchange online

Business Summary: Sopharma AD, formerly Sopharma AD Sofia, is a Bulgaria-based company engaged in the generic pharmaceutical industry. The Company specializes in the production and trade of medical substances and finished drug forms, as well as research and development in the field of medical products. Through the ampoule plant, tablet plant and the plant in Vrabevo it produces medicines, such as analgesics, antipyretics, cardiovascular medicines as well as drugs for respiratory disease treatment, among others. The Company offers its products under the brand Tribestan, Nivalin and Tabex, among others. In addition, it specializes in the gamma-sterilization of medical materials. It is the parent company of Sopharma Group and operates domestically and abroad in such countries as Russian Federation, Poland, Ukraine, Serbia, the United States and the United Kingdom, among others.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Sopharma AD revenues increased 23% to BGN2.64B. Net income increased 75% to BGN133.5M. Revenues reflect Sales of Goods increase of 23% to BGN2.24B, Sales of Products increase of 18% to BGN368M, Sales of Services increase of 21% to BGN23.4M. Net income benefited from Equity in Affiliates increase of 48% to BGN38.3M (income), Foreign Currency Exchange Rate Losses decrease of 80% to BGN438K (expense).